Antibodies against SARS-CoV-2 and its variants have become critically important weapons in the arsenal against COVID-19, contributing to the effort to save lives and reduce severe disease and hospitalization.

As SARS-CoV-2 has drifted antigenically from the Wuhan virus, to its Alpha, Beta, Gamma, Delta, and Omicron variants, antibodies in development have been brought forward to address each variant, including sometimes revisiting “older” antibodies that may work against new variants that arise.

Of all of the antibodies and targets tested for palliative therapy, it appears that only the anti-IL-6 receptor antibodies provide benefit for the immunological effects brought on by COVID-19 disease.

For all antibody-based approaches to treat COVID-19, the earliest possible treatment with high doses appear to be required for optimal activity and efficacy.